ARTICLE | Clinical News
AmBisome liposomal amphotericin B regulatory update
March 27, 2000 8:00 AM UTC
Canada granted marketing approval for AmBisome to treat systemic or disseminated Candida, Aspergillus or Cryptococcus fungal infections in patients who are refractory to or intolerant of conventional ...